Please assess the completion status of the following clinical trial:

Trial Title: Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women, 18-65 years of age;~* Participants must have a level of understanding sufficient to agree to all tests and examinations required by the protocol and must sign a written informed consent document;~* Participants must fulfill DSM-5 criteria for current civilian or combat-related PTSD~* Women must be using a medically accepted reliable means of contraception (if using an oral contraceptive medication, they must also be using a barrier contraceptive) or not be of childbearing potential (i.e., surgically sterile, postmenopausal for at least one year);~* Women of childbearing potential must have a negative pregnancy test at screening and prior to each intravenous infusion;~* Participants must be able to identify a family member, physician, or friend (i.e. someone who knows them well) who will participate in a Treatment Contract (and e.g. contact the study physician on their behalf in case manic symptoms or suicidal thoughts develop).~Exclusion criteria:~* Women who plan to become pregnant, are pregnant or are breast-feeding~* Serious, unstable medical illnesses such as hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic, or hematologic disease, including gastro-esophageal reflux disease, obstructive sleep apnea, history of difficulty with airway management during previous anesthetics, ischemic heart disease and uncontrolled hypertension, and history of severe head injury;~* Clinically significant abnormal findings of laboratory parameters, physical examination, or ECG;~* Renal impairment, as reflected by a BUN \>20 mg/dL, and/or creatinin clearance of \>1.3 mg/dL;~* Thyroid impairment, as reflected by TSH\> 4.2 mU/L Patients with uncorrected hypothyroidism or hyperthyroidism;~* Hormonal treatment (e.g., estrogen) started in the 3 months prior to the first infusion day;~* Use of evidence-based individual psychotherapy (such as prolonged exposure) during the study;~* History of autism, mental retardation, pervasive developmental disorders, or Tourette's syndrome; History of one or more seizures without a clear and resolved etiology;~* History of (hypo)mania;~* Past or current presence of psychotic symptoms, or diagnosis of a lifetime psychotic disorder including schizophrenia or schizoaffective disorder;~* Drug or alcohol abuse or dependence within the preceding 3 months~* Previous recreational use of ketamine or PCP;~* Current diagnosis of bulimia nervosa or anorexia nervosa;~* Diagnosis of schizotypal or antisocial personality disorder~* Patients judged clinically to be at serious and imminent suicidal or homicidal risk.~* A blood pressure of one reading over 160/90 or two separate readings over 140/90 at screen or baseline visits~* Patients who report current treatment with a benzodiazepine, an opioid medication, or a mood stabilizer (such as valproic acid or lithium) within 2 weeks prior to randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Experimental ketamine group (Type: EXPERIMENTAL): This arm will receive 0.5mg/kg repeated dose ketamine (6 infusions, 3 per week for 2 weeks).
- Active control midazolam group (Type: ACTIVE_COMPARATOR): This arm will receive 0.045mg/kg repeated dose midazolam (6 infusions, 3 per week for 2 weeks).

Based on this trial design, predict the completion outcome and termination type (if applicable).